Although lenalidomide use with dexamethasone has been reported in MM and insulin-binding antibodies,16 we believe this is the first reported successful use of combination therapy in SM with insulin-binding paraprotein, whereby disabling hypoglycaemia directed therapy. This evidence concerns the gene INS and Miyoshi myopathy.